Support HDYO

HDYO is the only organization who focus solely on supporting young people impacted by HD around the world. Will you help us?

<span class="translation_missing" title="translation missing: en.hdyo.land.loading">Loading</span>
Home Language and Accessibility What is HD? New to HD? Find Resources Research Ask for Help About HDYO News Videos PDF Resources Join Mailing List Kids Teens Young Adults Parents and Family JoHD Friends Professionals DONATE! Privacy Contact Us

An Update from Teva About AUSTEDO®

April 17, 2024

Huntington's Disease Youth Organization

HDYO has more information about HD available for young people, parents and professionals on our site:


Teva recently released the following press release looking at the effectiveness and patient satisfaction for HD chorea with the 4 week titration kit for AUSTEDO®.

Quick Notes

  • Titration of a medicine means slowly increasing the dose of a medicine by very small amounts over days, weeks, or even months, to find the right dose that is effective for you

  • Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results

  • START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4-week Titration Kit for AUSTEDO

  • AUSTEDO remains the only vesicular monoamine transporter 2 (VMAT2) inhibitor available with 3-year data for this progressive condition1,2

Read the Full Press Release

Our content is split into different groups. Choose the group that best describes your needs for more information on HD.

Kids Teens Young Adults Parents and Family JoHD Friends Professionals